Uncategorized
Viridian’s autoimmune eye disease shot passes Phase 3, but can it compete?
Viridian Therapeutics’ shares dropped Monday morning after a lackluster pivotal readout on its injection to treat thyroid eye disease.
Viridian’s pitch is that its drug, known as elegrobart, comes as an injection that can be …